Dupilumab versus placebo plus standard of care after hospitalization for COPD exacerbation

Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Dupixent plus standard of care with Placebo plus standard of care (2 arms). Primary endpoints: Time to first all-cause event and Number of moderate or severe COPD exacerbations. Planned start Aug 2026; status: authorised.